nach oben

Translational Stroke Research

Erschienen in:

01.04.2015 | Commentary

A Cost-Effective Rabbit Embolic Stroke Bioassay: Insight into the Development of Acute Ischemic Stroke Therapy

verfasst von: Paul A. Lapchak

Erschienen in: Translational Stroke Research | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Excerpt

This article was written to acknowledge the scientific achievement of Dr. Justin A. Zivin, the originator of the rabbit embolic stroke model and investigator responsible for the “translational stroke research” that led to the NINDS rt-PA trial and eventual approval of tissue plasminogen activator (tPA) for the treatment of acute ischemic stroke 20 years ago. In 1984–1985, the term “translational stroke research” did not exist, nor did this journal bearing the name Translational Stroke Research. Nevertheless, over the years, the rabbit embolic stroke model has been integral in the development and testing of novel therapies, and the model remains important for translational stroke therapy development. Translational Stroke Research has become an important means of disseminating advances in basic and translational stroke research and will be integral in future stroke therapy discovery. …

Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61(1):46–55.CrossRefPubMedCentralPubMed

Pan Y, Chen Q, Zhao X, Liao X, Wang C, Du W, et al. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China. PLoS ONE. 2014;9(10):e110525.CrossRefPubMedCentralPubMed

Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014;45(10):3032–9.CrossRefPubMed

del Zoppo G. Thrombolytic therapy in cerebrovascular disease. Curr Concepts Cereb Dis. 1988;23:7.

Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245–51.CrossRefPubMed

Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs. 2002;11(11):1623–32.CrossRefPubMed

Lapchak PA, Araujo DM, Zivin JA. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185(1):154–9.CrossRefPubMed

Lyden PD. Should all stroke patients receive tissue plasminogen activator therapy, despite mild or improving symptoms? Nat Clin Pract Cardiovasc Med. 2006;3(4):184–5.CrossRefPubMed

Lyden PD, Lees KR, Davis SM. Alteplase for acute stroke revisited: the first 10 years. Lancet Neurol. 2006;5(9):722–4.CrossRefPubMed

10.

Lyden PD, Zivin JA, Clark WA, Madden K, Sasse KC, Mazzarella VA, et al. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology. 1989;39:703.CrossRefPubMed

11.

Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–74.CrossRefPubMed

12.

Hacke W, editor Thrombolysis, Thrombectomy and Acute Stroke Therapy Conference. Thrombolysis, Thrombectomy and Acute Stroke Therapy Conference; 2014; Heidelberg - Mannheim.

13.

Lyden P, Lapchak P. Sisyphus and translational stroke research. Sci Transl Med. 2012;4(156):156ps20.CrossRefPubMed

14.

Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 1985;230(4731):1289.CrossRefPubMed

15.

Zivin JA, Simmons J. tPA for stroke : the story of a controversial drug. New York: Oxford University Press; 2011. xiv, 191 p. p.

16.

Lapchak PA, Zhang JH. Translational stroke research : from target selection to clinical trials. New York: Springer; 2012. xxiv, 923 p. p.CrossRef

17.

Lyden PD. Thrombolytic therapy for acute stroke. 2nd ed. Totowa, N.J: Humana Press; 2005. xvii, 370 p. p.CrossRef

18.

Lyden PD. Thrombolytic therapy for stroke. Totowa, N.J: Humana Press; 2001. xiv, 410 p. p.CrossRef

19.

Lyden PD. Thrombolytic therapy for acute stroke. New York: Springer; 2014. pages cm p.

20.

Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010;1(2):96–107.CrossRefPubMedCentralPubMed

21.

Lapchak PA. A clinically relevant rabbit embolic stroke model for acute ischemic stroke therapy development: mechanisms & targets. In: Lapchak PA, Zhang JH, editors. Translational Stroke Research: From Target Selection to Clinical Trials. USA: Springer; 2012. p. 541–84.CrossRef

22.

O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3):467–77.CrossRefPubMed

23.

Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752–8.

24.

Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187–91.CrossRefPubMedCentralPubMed

25.

Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3):841–3.CrossRefPubMed

26.

Kawaguchi M, Furuya H, Patel PM. Neuroprotective effects of anesthetic agents. J Anesth. 2005;19(2):150–6.CrossRefPubMed

27.

Sanders RD, Ma D, Maze M. Anaesthesia induced neuroprotection. Best Pract Res Clin Anaesthesiol. 2005;19(3):461–74.CrossRefPubMed

28.

Head BP, Patel P. Anesthetics and brain protection. Curr Opin Anaesthesiol. 2007;20(5):395–9.CrossRefPubMed

29.

Schifilliti D, Grasso G, Conti A, Fodale V. Anaesthetic-related neuroprotection: intravenous or inhalational agents? CNS Drugs. 2010;24(11):893–907.PubMed

30.

Wei H, Inan S. Dual effects of neuroprotection and neurotoxicity by general anesthetics: role of intracellular calcium homeostasis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:156–61.CrossRefPubMed

31.

Combes RD. A critical review of anaesthetised animal models and alternatives for military research, testing and training, with a focus on blast damage, haemorrhage and resuscitation. Altern Lab Anim : ATLA. 2013;41(5):385–415.PubMed

32.

Burchell SR, Dixon BJ, Tang J, Zhang JH. Isoflurane provides neuroprotection in neonatal hypoxic ischemic brain injury. J Investig Med. 2013;61(7):1078–83.PubMedCentralPubMed

33.

Karmarkar SW, Bottum KM, Tischkau SA. Considerations for the use of anesthetics in neurotoxicity studies. Comp Med. 2010;60(4):256–62.PubMedCentralPubMed

34.

Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22(9):391–7.CrossRefPubMed

35.

Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181–98.CrossRefPubMedCentralPubMed

36.

Lapchak PA, Wei J, Zivin JA. Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke. 2004;35(8):1985–8.CrossRefPubMed

37.

Zivin JA, Waud DR. Quantal bioassay and stroke. Stroke. 1992;23(5):767–73.CrossRefPubMed

38.

Lyden P, Pereira B, Chen B, Zhao L, Lamb J, Lei IF, et al. Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. Stroke. 2014;45(3):896–9.CrossRefPubMedCentralPubMed

39.

Lapchak PA, Chapman DF, Nunez SY, Zivin JA. Dehydroepiandrosterone sulfate is neuroprotective in a reversible spinal cord ischemia model: possible involvement of GABA (A) receptors. Stroke. 2000;31:1953–6.CrossRefPubMed

40.

Turner R, Jickling G, Sharp F. Are underlying assumptions of current animal models of human stroke correct: from STAIRS to high hurdles? Transl Stroke Res. 2011;2(2):138–43.CrossRefPubMedCentralPubMed

41.

Jickling GC, Sharp FR. Improving the translation of animal ischemic stroke studies to humans. Metab Brain Dis. 2014.

42.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.

43.

Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39(6):1751–8.CrossRefPubMed

44.

Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354(6):588–600.CrossRefPubMed

45.

Hacke W, Schellinger PD, Albers GW, Bornstein NM, Dahlof BL, Fulton R, et al. Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial. Stroke. 2014;45(11):3187–93.CrossRefPubMed

46.

Patel R, Ispoglou S, Apostolakis S. Desmoteplase as a potential treatment for cerebral ischaemia. Expert Opin Investig Drugs. 2014;23(6):865–73.CrossRefPubMed

47.

Piechowski-Jozwiak B, Bogousslavsky J. The use of desmoteplase (bat saliva) in the treatment of ischaemia. Expert Opin Biol Ther. 2013;13(3):447–53.CrossRefPubMed

48.

von Kummer R, Albers GW, Mori E, Committees DS. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. Int J Stroke. 2012;7(7):589–96.CrossRef

49.

Paciaroni M, Medeiros E, Bogousslavsky J. Desmoteplase. Expert Opin Biol Ther. 2009;9(6):773–8.CrossRefPubMed

50.

Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25(11):2220–6.CrossRefPubMed

51.

Waud DR. On biological assays involving quantal responses. J Pharmacol Exp Ther. 1972;183(3):577–607.PubMed

52.

NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.CrossRef

53.

Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11(10):1753–63.CrossRefPubMedCentralPubMed

54.

Lapchak PA. Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model. Brain Res. 2009;1294:211–7.CrossRefPubMed

55.

Lapchak PA, Song D, Wei J, Zivin JA. Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence. Exp Neurol. 2004;188(2):286–91.CrossRefPubMed

56.

Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145–50.CrossRefPubMed

57.

Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002;2(1):38–43.CrossRefPubMed

58.

Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007;12(1):97–112.CrossRefPubMed

59.

Lapchak PA, Araujo DM. Advances in hemorrhagic stroke therapy: conventional and novel approaches. Expert Opin Emerg Drugs. 2007;12(3):389–406.CrossRefPubMed

60.

Lyden PD, Madden KP, Clark WM, Sasse KC, Zivin JA. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke. 1990;21(11):1589–93.CrossRefPubMed

61.

Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5(1):1–16.PubMed

62.

Lyden PD, Zivin JA, Soll M, Sitzer M, Rothrock JF, Alksne J. Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. Arch Neurol. 1987;44(8):848–50.CrossRefPubMed

63.

Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31(12):3034–40.CrossRefPubMed

64.

Fagan SC, Lapchak PA, Liebeskind DS, Ishrat T, Ergul A. Recommendations for preclinical research in hemorrhagic transformation. Transl Stroke Res. 2013;4(3):322–7.CrossRefPubMedCentralPubMed

65.

Levine SR, Hill MD. NeuroThera Effectiveness and Safety Trial 3: how do we align corporate and scientific integrity to complete and report pharma-sponsored trials properly? Stroke. 2014;45(11):3175–7.CrossRefPubMed

66.

Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4(3):279–85.CrossRefPubMedCentralPubMed

67.

Lapchak PA. Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules. Transl Stroke Res. 2013;4(3):328–42.CrossRefPubMedCentralPubMed

68.

Keep RF, Wang MM, Xiang J, Hua Y, Xi G. Full steam ahead with remote ischemic conditioning for stroke. Transl Stroke Res. 2014;5(5):535–7.CrossRefPubMed

69.

Liu X, Zhao S, Liu F, Kang J, Xiao A, Li F, et al. Remote ischemic postconditioning alleviates cerebral ischemic injury by attenuating endoplasmic reticulum stress-mediated apoptosis. Transl Stroke Res. 2014;5(6):692–700.CrossRefPubMed

70.

Bahjat FR, Gesuete R, Stenzel-Poore MP. Steps to translate preconditioning from basic research to the clinic. Transl Stroke Res. 2013;4(1):89–103.CrossRefPubMedCentralPubMed

71.

Tajiri N, Dailey T, Metcalf C, Mosley YI, Lau T, Staples M, et al. In vivo animal stroke models: a rationale for rodent and non-human primate models. Transl Stroke Res. 2013;4(3):308–21.CrossRefPubMedCentralPubMed

72.

Rosell A, Agin V, Rahman M, Morancho A, Ali C, Koistinaho J, et al. Distal occlusion of the middle cerebral artery in mice: are we ready to assess long-term functional outcome? Transl Stroke Res. 2013;4(3):297–307.CrossRefPubMed

73.

Kristian T, Hu B. Guidelines for using mouse global cerebral ischemia models. Transl Stroke Res. 2013;4(3):343–50.CrossRefPubMed

74.

Nobile CW, Palmateer JM, Kane J, Hurn PD, Schallert T, Adkins DL. Impaired limb reaction to displacement of center of gravity in rats with unilateral striatal ischemic injury. Transl Stroke Res. 2014;5(5):562–8.CrossRefPubMed

75.

Kunze A, Zierath D, Drogomiretskiy O, Becker K. Variation in behavioral deficits and patterns of recovery after stroke among different rat strains. Transl Stroke Res. 2014;5(5):569–76.CrossRefPubMed

Titel: A Cost-Effective Rabbit Embolic Stroke Bioassay: Insight into the Development of Acute Ischemic Stroke Therapy
verfasst von: Paul A. Lapchak
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: Translational Stroke Research / Ausgabe 2/2015
Print ISSN: 1868-4483
Elektronische ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-015-0386-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A Cost-Effective Rabbit Embolic Stroke Bioassay: Insight into the Development of Acute Ischemic Stroke Therapy

Excerpt

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Perihematoma Edema: A Potential Translational Target in Intracerebral Hemorrhage?

Warfarin Pretreatment Reduces Cell Death and MMP-9 Activity in Experimental Intracerebral Hemorrhage

The Effect of Different Doses and Different Routes of Acetylsalicylic Acid Administration on Platelet Aggregation in Healthy Volunteers and Ischemic Stroke Patients

Long-term Effect of Telmisartan on Alzheimer’s Amyloid Genesis in SHR-SR After tMCAO

Brainstem Opioidergic System Is Involved in Early Response to Experimental SAH

Chronic Hydrocephalus and Perihematomal Tissue Injury Developed in a Rat Model of Intracerebral Hemorrhage with Ventricular Extension

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie